Sugi Predict

Sugi Predict / Compounds / SCHEMBL975946

SCHEMBL975946

SCHEMBL975946

O=C(O)c1ccccc1OC(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.55
▸ HSD17B10 Q99714 6/20 0.55
▸ HPGD P15428 5/20 0.55
▸ ALDH1A1 P00352 8/20 0.53
▸ ESR1 P03372 1/20 0.53
▸ ITGB3 P05106 1/20 0.53
▸ ITGA2B P08514 1/20 0.53
▸ HMGB1 P09429 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ GGT1 P19440 1/20 0.53
▸ PTGS1 P23219 1/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ BLM P54132 1/20 0.53
▸ NAPRT Q6XQN6 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ TAS2R14 Q9NYV8 1/20 0.53
▸ MAPT P10636 2/20 0.52
▸ USP2 O75604 1/20 0.52
▸ PDE3A Q14432 1/20 0.52
▸ KMT2A Q03164 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28452350 0.94 KDM4E (0.50) KDM4EHSD17B10HPGDALDH1A1ESR1
SCHEMBL20516072 0.86 KDM4E (0.53) KDM4EHSD17B10HPGDALDH1A1ESR1
SCHEMBL11212937 0.86 HTT (0.49) KDM4EALDH1A1TDP1MAPTKMT2A
SCHEMBL21357575 0.85 KDM4E (0.51) KDM4EHSD17B10HPGDALDH1A1ESR1
SCHEMBL18700962 0.85 KDM4E (0.59) KDM4EHSD17B10HPGDALDH1A1ESR1
SCHEMBL5744926 0.85 KDM4E (0.51) KDM4EHSD17B10HPGDALDH1A1ESR1
SCHEMBL30668163 0.83 MAPT (0.54) ALDH1A1TSHRMAPTHTTSMN1; SMN2
SCHEMBL5073351 0.83 MAPT (0.54) ALDH1A1TSHRMAPTHTTSMN1; SMN2
SCHEMBL27051923 0.83 ALB (0.52) KDM4EHSD17B10HPGDALDH1A1ESR1
SCHEMBL1286684 0.82 IRAK4 (0.53) KDM4EALDH1A1KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 — — CN claimed
EP-4065577-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES Bayer Aktiengesellschaft (DE) 2022-10-05 — — EP claimed
WO-2021105091-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 — — WO claimed
EP-2776395-A2 PROCESS FOR THE PREPARATION OF ROFLUMILAST Mylan Laboratories, Limited (IN) 2014-09-17 — — EP claimed
WO-2013072938-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF ROFLUMILAST MYLAN LABORATORIES LTD (IN) 2013-05-23 — — WO claimed
JP-4742026-B2 — — 2011-08-10 — — JP claimed
WO-2009067547-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 — — WO claimed
EP-1606261-A1 NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST ALTANA Pharma AG (DE) 2005-12-21 — — EP claimed
WO-2004080967-A1 NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST ALTANA PHARMA AG (DE) 2004-09-23 — — WO claimed
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US disclosed
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2026-05-19 — — US disclosed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 — — WO disclosed
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 — — US disclosed
US-12577206-B2 Pyrazolone formyl peptide 2 receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2026-03-17 — — US disclosed
WO-2006012577-A2 QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE BAYER PHARMACEUTICALS CORPORATION (US) 2006-02-02 — — WO disclosed
US-20050234090-A1 Modulators of chemokine receptor activity PFIZER INC 2005-10-20 — — US disclosed
US-6821964-B2 FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH MONOCYTE ACCUMULATION, LYMPHOCYTE ACCUMULATION OR LEUCOCYTE ACCUMULATION PFIZER INC 2004-11-23 — — US disclosed
EP-1368354-A1 MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Pfizer Products Inc. (US) 2003-12-10 — — EP disclosed
US-20030008893-A1 Modulators of chemokine receptor activity COLON-CRUZ ROBERTO (US) 2003-01-09 — — US disclosed
WO-2002070523-A1 MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY PFIZER PRODUCTS INC. (US) 2002-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577206-B2 Pyrazolone formyl peptide 2 receptor agonists FPR2, FPR1, FPR3 KDM4E 4709/4885HSD17B10 1460/4885HPGD 557/4885
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 LCLAT1, LPCAT1, ACAT2 KDM4E 3151/4885HSD17B10 609/4885HPGD 3466/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B KDM4E 907/4885HSD17B10 910/4885HPGD 1121/4885
US-20030008893-A1 Modulators of chemokine receptor activity CCR1, CCR3, CCR2 KDM4E 4790/4885HSD17B10 2587/4885HPGD 745/4885
US-12630549-B2 Pyrazoleamide derivatives CYP11B2, CYP11B1, ADRA1B KDM4E 3127/4885HSD17B10 882/4885HPGD 1203/4885
US-20050234090-A1 Modulators of chemokine receptor activity CCR3, CCR2, CCR1 KDM4E 4766/4885HSD17B10 2659/4885HPGD 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.